terbutaline has been researched along with Disease Exacerbation in 8 studies
Terbutaline: A selective beta-2 adrenergic agonist used as a bronchodilator and tocolytic.
terbutaline : A member of the class of phenylethanolamines that is catechol substituted at position 5 by a 2-(tert-butylamino)-1-hydroxyethyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Formoterol therapy was at least as effective as terbutaline therapy in children and adolescents with mild and moderate asthma exacerbations." | 9.14 | A randomized, comparative study of formoterol and terbutaline dry powder inhalers in the treatment of mild to moderate asthma exacerbations in the pediatric acute care setting. ( Bussamra, MH; Cukier, A; Rodrigues, JC; Stelmach, R, 2009) |
| "We analyzed daily peak expiratory flow and symptom scores recorded by participants in the SAKURA study (NCT00839800), an international multicentre randomized controlled trial comparing budesonide/formoterol as maintenance and reliever therapy versus budesonide/formoterol maintenance plus terbutaline as reliever, in adults with persistent asthma." | 5.41 | Detecting asthma exacerbations using daily home monitoring and machine learning. ( Gonem, S; Minku, LL; Zhang, O, 2021) |
| "The PRACTICAL study was a 52-week, open-label, parallel group, randomised controlled trial of 890 adults with mild to moderate asthma, who were randomised to budesonide/formoterol Turbuhaler 200/6mcg one actuation as required or budesonide Turbuhaler 200mcg one actuation twice daily and terbutaline Turbuhaler 250mcg two actuations as required." | 5.34 | Combination budesonide/formoterol inhaler as sole reliever therapy in Māori and Pacific people with mild and moderate asthma. ( Baggott, C; Fingleton, J; Hancox, RJ; Hardy, J; Harwood, M; Holliday, M; Semprini, A; Tewhaiti-Smith, J; Weatherall, M, 2020) |
| "Formoterol therapy was at least as effective as terbutaline therapy in children and adolescents with mild and moderate asthma exacerbations." | 5.14 | A randomized, comparative study of formoterol and terbutaline dry powder inhalers in the treatment of mild to moderate asthma exacerbations in the pediatric acute care setting. ( Bussamra, MH; Cukier, A; Rodrigues, JC; Stelmach, R, 2009) |
| " Effectiveness of switch was assessed as the proportion without severe asthma exacerbation and the proportion achieving risk domain asthma control (RDAC; no asthma-related hospitalization, antibiotics without upper respiratory diagnosis or acute course of oral corticosteroids) and overall asthma control (OAC; RDAC and ≤ 200 μg salbutamol/≤500 μg terbutaline average daily dose) comparing 1 year after and before the switch." | 3.91 | Real-life effectiveness of inhaler device switch from dry powder inhalers to pressurized metred-dose inhalers in patients with asthma treated with ICS/LABA. ( Ban, GY; Carter, V; Hardjojo, A; Jie, JLZ; Lee, HY; Park, HS; Price, DB; Van Boven, JFM; Wan Yau Ming, S; Yoon, D, 2019) |
| "For the acute COPD studies, one was double-blind and randomised, one was single-blind and randomised, and one was open-label." | 2.45 | Use of dry powder inhalers in acute exacerbations of asthma and COPD. ( Borgström, L; Ingelf, J; Selroos, O, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 4 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, O | 1 |
| Minku, LL | 1 |
| Gonem, S | 1 |
| Hardy, J | 1 |
| Tewhaiti-Smith, J | 1 |
| Baggott, C | 1 |
| Fingleton, J | 1 |
| Semprini, A | 1 |
| Holliday, M | 1 |
| Hancox, RJ | 1 |
| Weatherall, M | 1 |
| Harwood, M | 1 |
| Crossingham, I | 1 |
| Turner, S | 1 |
| Ramakrishnan, S | 1 |
| Fries, A | 1 |
| Gowell, M | 1 |
| Yasmin, F | 1 |
| Richardson, R | 1 |
| Webb, P | 1 |
| O'Boyle, E | 1 |
| Hinks, TS | 1 |
| Matheny, M | 1 |
| Maleque, N | 1 |
| Channell, N | 1 |
| Eisch, AR | 1 |
| Auld, SC | 1 |
| Banerji, A | 1 |
| Druey, KM | 1 |
| Steurer, J | 1 |
| Park, HS | 1 |
| Yoon, D | 1 |
| Lee, HY | 1 |
| Ban, GY | 1 |
| Wan Yau Ming, S | 1 |
| Jie, JLZ | 1 |
| Carter, V | 1 |
| Hardjojo, A | 1 |
| Van Boven, JFM | 1 |
| Price, DB | 1 |
| Selroos, O | 1 |
| Borgström, L | 1 |
| Ingelf, J | 1 |
| Bussamra, MH | 1 |
| Stelmach, R | 1 |
| Rodrigues, JC | 1 |
| Cukier, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Comparison of Symbicort® SMART (160/4.5μg) and Symbicort® Turbuhaler 160/4.5 μg, Plus Terbutaline Turbuhaler 0.4 mg as Needed, for Treatment of Asthma - a 12-month, Randomized, Double-blind, Parallel Group, Active-controlled, Multinational Phase III Stu[NCT00839800] | Phase 3 | 2,091 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The ACQ developed by Juniper and colleagues (Juniper et al 1999) was used without the FEV1 and Beta 2-agonist questions. The Asthma Control Questionnaire has 5 questions that are assessed on a 7-point scale from 0 to 6 where 0 represents good control and 6 represents poor control. The overall score is the mean of the five responses. At least 4 out of the 5 questions must have been answered to provide a value. The mean of the overall score for Weeks 4 to 52 was presented here. (NCT00839800)
Timeframe: 4, 12, 24, 36 and 52 weeks after randomization
| Intervention | units on a scale (Mean) |
|---|---|
| Symbicort SMART | 1.162 |
| Symbicort+Terbutaline As Needed | 1.289 |
The mean value from the treatment period for Total Asthma Symptom Score (total score: 0 is best - no asthma symptoms; 6 is worst). (NCT00839800)
Timeframe: 52-week treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Symbicort SMART | 1.12 |
| Symbicort+Terbutaline As Needed | 1.22 |
The mean value from a 52-week treatment period. (NCT00839800)
Timeframe: 2-week run-in period (14 - 18 days before randomization - week 0) and a 52-week treatment period
| Intervention | L/min (Mean) |
|---|---|
| Symbicort SMART | 334.2 |
| Symbicort+Terbutaline As Needed | 327.8 |
The mean value for Weeks 4, 12, 24, 36 and 52 was analysed. (NCT00839800)
Timeframe: 4, 12, 24, 36 and 52 weeks after randomization
| Intervention | Liter (L) (Geometric Mean) |
|---|---|
| Symbicort SMART | 2.258 |
| Symbicort+Terbutaline As Needed | 2.222 |
The mean value from a 52-week treatment period. (NCT00839800)
Timeframe: 52-week treatment period
| Intervention | Liter/minute (L/min) (Mean) |
|---|---|
| Symbicort SMART | 331.8 |
| Symbicort+Terbutaline As Needed | 324.7 |
The mean value from the treatment period was presented here. (NCT00839800)
Timeframe: 52-week treatment period
| Intervention | Nights With Awakening(s) (Mean) |
|---|---|
| Symbicort SMART | 15.7 |
| Symbicort+Terbutaline As Needed | 17.5 |
Asthma exacerbation was defined as deterioration in asthma leading to oral GCS treatment, hospitalization, or ER treatment. Number of asthma exacerbations during 52 weeks treatment was presented here. (NCT00839800)
Timeframe: up to 52 weeks
| Intervention | Asthma exacerbations (Number) |
|---|---|
| Symbicort SMART | 259 |
| Symbicort+Terbutaline As Needed | 363 |
An as-needed-free day is defined as a night and day with no use of as-needed medication. The mean value from the treatment period was presented here. (NCT00839800)
Timeframe: 52-week treatment period
| Intervention | percentage of as-needed-free days (Mean) |
|---|---|
| Symbicort SMART | 51.4 |
| Symbicort+Terbutaline As Needed | 47.2 |
An asthma-control day was defined as a a night and day with no asthma symptoms, no awakenings due to asthma symptoms, and no as-needed medication use. The mean value from the treatment period was presented here. (NCT00839800)
Timeframe: 52-week treatment period
| Intervention | percentage of asthma-control days (Mean) |
|---|---|
| Symbicort SMART | 41.7 |
| Symbicort+Terbutaline As Needed | 37.9 |
A symptom-free day was defined as a day without daytime or night-time symptoms and without night-time awakenings due to asthma symptoms. The mean value was presented here. (NCT00839800)
Timeframe: 52-week treatment period
| Intervention | symptom-free days (Mean) |
|---|---|
| Symbicort SMART | 45.5 |
| Symbicort+Terbutaline As Needed | 41.6 |
Asthma exacerbation was defined as deterioration in asthma leading to oral glucocorticosteroid [GCS] treatment, hospitalization, or emergency room [ER] treatment. (NCT00839800)
Timeframe: week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Symbicort SMART | 16 |
| Symbicort+Terbutaline As Needed | 22 |
Mild asthma exacerbation was defined as morning PEF ≥20% below baseline, daily as-needed medication use ≥2 inhalations above baseline, or a night with awakening due to asthma symptoms. The percentage of participants who had experienced mild asthma exacerbation(s) at the end of the study was presented here. (NCT00839800)
Timeframe: up to 52 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Symbicort SMART | 71 |
| Symbicort+Terbutaline As Needed | 80 |
The mean value of total daily number of inhalations from the treatment period for use of as-needed medication (daytime, night-time). (NCT00839800)
Timeframe: 52-week treatment period
| Intervention | inhalations/day (Mean) |
|---|---|
| Symbicort SMART | 1.21 |
| Symbicort+Terbutaline As Needed | 1.46 |
2 reviews available for terbutaline and Disease Exacerbation
| Article | Year |
|---|---|
Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma.
Topics: Adolescent; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Adult; Anti-Asthmatic Agen | 2021 |
Use of dry powder inhalers in acute exacerbations of asthma and COPD.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Disease Progression; Ethanolamin | 2009 |
4 trials available for terbutaline and Disease Exacerbation
| Article | Year |
|---|---|
Detecting asthma exacerbations using daily home monitoring and machine learning.
Topics: Asthma; Bronchodilator Agents; Budesonide; Disease Progression; Drug Combinations; Female; Formotero | 2021 |
Combination budesonide/formoterol inhaler as sole reliever therapy in Māori and Pacific people with mild and moderate asthma.
Topics: Administration, Inhalation; Adult; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Budesonide; | 2020 |
Topics: Administration, Inhalation; Adult; Asthma; Budesonide; Budesonide, Formoterol Fumarate Drug Combinat | 2018 |
A randomized, comparative study of formoterol and terbutaline dry powder inhalers in the treatment of mild to moderate asthma exacerbations in the pediatric acute care setting.
Topics: Administration, Inhalation; Asthma; Child; Disease Progression; Emergency Medical Services; Ethanola | 2009 |
2 other studies available for terbutaline and Disease Exacerbation
| Article | Year |
|---|---|
Severe Exacerbations of Systemic Capillary Leak Syndrome After COVID-19 Vaccination: A Case Series.
Topics: Aged; Capillary Leak Syndrome; Cardiovascular Agents; COVID-19; COVID-19 Vaccines; Disease Progressi | 2021 |
Real-life effectiveness of inhaler device switch from dry powder inhalers to pressurized metred-dose inhalers in patients with asthma treated with ICS/LABA.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists | 2019 |